share_log

Apollomics | 424B3: Prospectus

Apollomics | 424B3: Prospectus

Apollomics | 424B3:募資說明書
美股sec公告 ·  04/25 05:15
牛牛AI助理已提取核心訊息
Apollomics Inc., a biopharmaceutical company, has announced a potential offering of up to $200 million in securities, which may include Class A Ordinary Shares, debt securities, rights, warrants, and units. This offering is detailed in a prospectus filed pursuant to Rule 424(b)(3) with the SEC under Registration No. 333-278430. The securities may be offered in various combinations and series, with specific terms to be determined at the time of each offering. A prospectus supplement will provide details about the offering and the securities offered. Apollomics' Class A Ordinary Shares and warrants are listed on the Nasdaq under the symbols 'APLM' and 'APLMW,' respectively. As of April 17, 2024, the closing prices for these shares and warrants were $0.53 and $0.02, respectively. The company's public float...Show More
Apollomics Inc., a biopharmaceutical company, has announced a potential offering of up to $200 million in securities, which may include Class A Ordinary Shares, debt securities, rights, warrants, and units. This offering is detailed in a prospectus filed pursuant to Rule 424(b)(3) with the SEC under Registration No. 333-278430. The securities may be offered in various combinations and series, with specific terms to be determined at the time of each offering. A prospectus supplement will provide details about the offering and the securities offered. Apollomics' Class A Ordinary Shares and warrants are listed on the Nasdaq under the symbols 'APLM' and 'APLMW,' respectively. As of April 17, 2024, the closing prices for these shares and warrants were $0.53 and $0.02, respectively. The company's public float was valued at approximately $58.7 million based on a closing sale price of $0.73 on April 1, 2024. Apollomics is an emerging growth company and a foreign private issuer, which exempts it from certain SEC reporting requirements. The company is incorporated in the Cayman Islands with operations in the U.S. and China through wholly-owned subsidiaries. The offering aims to raise capital for general corporate purposes, which may include working capital, capital expenditures, and potential acquisitions.
生物製藥公司Apollomics Inc. 宣佈可能發行高達2億美元的證券,其中可能包括A類普通股、債務證券、權利、認股權證和單位。根據第424(b)(3)條向美國證券交易委員會提交的招股說明書詳細介紹了本次發行,註冊號爲333-278430。證券可以以不同的組合和系列發行,具體條款將在每次發行時確定。招股說明書補充文件將提供有關此次發行和所發行證券的詳細信息。Apollomics的A類普通股和認股權證分別以'APLM'和'APLMW'的代碼在納斯達克上市。截至2024年4月17日,這些股票和認股權證的收盤價分別爲0.53美元和0.02美元。根據2024年4月1日0.73美元的收盤價,該公司的...展開全部
生物製藥公司Apollomics Inc. 宣佈可能發行高達2億美元的證券,其中可能包括A類普通股、債務證券、權利、認股權證和單位。根據第424(b)(3)條向美國證券交易委員會提交的招股說明書詳細介紹了本次發行,註冊號爲333-278430。證券可以以不同的組合和系列發行,具體條款將在每次發行時確定。招股說明書補充文件將提供有關此次發行和所發行證券的詳細信息。Apollomics的A類普通股和認股權證分別以'APLM'和'APLMW'的代碼在納斯達克上市。截至2024年4月17日,這些股票和認股權證的收盤價分別爲0.53美元和0.02美元。根據2024年4月1日0.73美元的收盤價,該公司的公衆持股量約爲5,870萬美元。Apollomics是一家新興成長型公司,也是一家外國私人發行人,這使其不受美國證券交易委員會的某些報告要求的約束。該公司在開曼群島註冊成立,通過全資子公司在美國和中國開展業務。此次發行旨在爲一般公司用途籌集資金,其中可能包括營運資金、資本支出和潛在的收購。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。